Actively Recruiting
Study Evaluating CAR-T Cell Therapy for Chronic or Refractory Primary Immune Thrombocytopenia ITP Testing Safety and Effectiveness in Patients Ages 8 to 75
Led by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Updated on 2024-07-22
10
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of CAR-T cell therapy for patients with chronic or refractory primary Immune Thrombocytopenia ITP, a condition where the immune system attacks platelets. This open-label, single-arm clinical trial aims to provide new treatment options for those who have not responded well to standard therapies. The study is being conducted at a single center and sponsored by the 920th Hospital of Joint Logistics Support Force of Peoples Liberation Army of China. After patients join the study, their immune cells are collected through a procedure called leukapheresis to create CAR-T cells. Before receiving these modified cells by intravenous infusion, participants undergo a 3-5 day lymphodepletion treatment with fludarabine and cyclophosphamide to prepare their bodies. Following the infusion, patients are monitored closely for up to 12 weeks to evaluate safety and treatment response. Those showing lasting remission after 12 weeks will be followed for at least one year to assess long-term disease control. During the trial, participants will have regular assessments including physical exams, laboratory tests, and monitoring for adverse effects. The main outcome measured is the portion of patients who respond to treatment at least two weeks after infusion. Other outcomes include complete response rates, relapse rates, and duration of response. Safety events are tracked for up to 12 months. Overall participation may last over a year depending on individual response and follow-up needs.
CONDITIONS
Brief Title
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Research Team
S
Sanbin Wang, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here